ATA188 + Placebo
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Progressive Multiple Sclerosis
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Trial Timeline
Oct 19, 2017 → Jan 17, 2024
NCT ID
NCT03283826About ATA188 + Placebo
ATA188 + Placebo is a phase 1/2 stage product being developed by Atara Biotherapeutics for Primary Progressive Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03283826. Target conditions include Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03283826 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Primary Progressive Multiple Sclerosis